Contributors

About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« IPO Releases List of Top 300 Patent Holders for 2012 | Main | News from Abroad: UK Court of Appeal Rules on Interim Injunctions »

June 25, 2013

Comments

Kevin,

May be it's a good thing that SCOTUS didn't grant cert and thus potentially affirm Moore's flawed opinion in Momenta as to what is entitled to the "safe harbor" under Hatch-Waxman. With contrary view expressed in Classen Immunotherapies, there's still the opportunity for an en banc ruling by the Federal Circuit.

The comments to this entry are closed.

November 2023

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30